This proposal by a new investigator examines decisions made by advanced cancer patients regarding early phase clinical trials. Advances in basic and translational research may herald the arrival of new, targeted therapies that will improve cancer treatment and reduce mortality, but all of these therapies must be tested for safety in early phase (EP) clinical trials before they can benefit the public. Recruiting more patients to EP trials may speed the development of new cancer therapies, and some have argued that trials Developing new cancer therapies is a national priority, but the advanced cancer patients in whom these therapies are first tested are highly vulnerable. This study examines how advanced cancer patients make decisions about participating in a trial of a new therapy. The study aims to gather information that can improve the system for developing cancer therapies without putting vulnerable cancer patients at undue risk.
Aim 3 analyzes ACC patientsPublic Health Relevance
Garrett, Sarah B; Koenig, Christopher J; Trupin, Laura et al. (2017) What advanced cancer patients with limited treatment options know about clinical research: a qualitative study. Support Care Cancer 25:3235-3242 |
Dohan, Daniel; Garrett, Sarah B; Rendle, Katharine A et al. (2016) The Importance Of Integrating Narrative Into Health Care Decision Making. Health Aff (Millwood) 35:720-5 |
Abramson, Corey M; Dohan, Daniel (2015) BEYOND TEXT: USING ARRAYS TO REPRESENT AND ANALYZE ETHNOGRAPHIC DATA. Sociol Methodol 45:272-319 |
Koenig, Christopher J; Ho, Evelyn Y; Trupin, Laura et al. (2015) An exploratory typology of provider responses that encourage and discourage conversation about complementary and integrative medicine during routine oncology visits. Patient Educ Couns 98:857-63 |